Biological Drug

PreclinicalSmall molecule

Biological Drug is one of 129 small molecule programs targeting Juvenile Idiopathic Arthritis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

128

Competitors

Pipeline

Status by Indication[3][1]

Indication

Juvenile Idiopathic ArthritisActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Ulcerative ColitisActive, not recruiting

AsthmaActive, not recruiting

Juvenile Idiopathic ArthritisPreclinical

Active, not recruiting

Rheumatoid ArthritisPreclinical

Active, not recruiting

Ulcerative ColitisPreclinical

Active, not recruiting

AsthmaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

46 2

Xolair

Roche

Preclinical

25 3

Singulair

AstraZeneca

Preclinical

17 4

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 5

Cinqair

Teva

Preclinical

13 6

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 7

Asmanex

Novartis

Preclinical

5 8

Celexa

AbbVie

Preclinical

1 9

Spiriva

Boehringer Ingelheim

Preclinical

8 10

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Post-ApprovalRecruiting

Biological Therapy

NCT05169593

Clinical

Trials by Indication[1]

Rheumatoid Arthritis1 trial

Outcomes of Biological Therapy on Rheumatoid Arthritis

Unknown status·SSohag University··NCT05267431·200 enrolled

Ulcerative Colitis1 trial

Hematological Indices and Fecal Calprotectin Predict Histological Remission in Ulcerative Colitis

Unknown status·—··NCT04818788·24 enrolled

Asthma1 trial

Fluctuation Analyses of Asthma Patients With Biologics Use

Unknown status·—··NCT06024707·48 enrolled

Biological Therapy1 trial

Prevention of Postoperative Endoscopic Recurrence with Endoscopy-driven Versus Systematic Biological Therapy

Recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 4·NCT05169593·292 enrolled

Juvenile Idiopathic Arthritis1 trial

Articular Damage in Patients With Juvenile Idiopathic Arthritis After Transition to Adult Care

Not yet recruiting·IIRCCS Burlo Garofolo··NCT06895278·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Biological Drug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biological Drug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biological Drug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universitaire Ziekenhuizen KU Leuven company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversitaire Ziekenhuizen KU Leuven

Biological Drug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Rheumatoid Arthritis1 trial

Ulcerative Colitis1 trial

Asthma1 trial

Biological Therapy1 trial

Juvenile Idiopathic Arthritis1 trial

References

Drug Info

Quick Facts

Related News